Core Viewpoint - The successful completion of the first HX robotic arm-assisted total knee arthroplasty at the Fourth Medical Center of the Chinese People's Liberation Army signifies a significant advancement in the clinical application of domestic orthopedic surgical robots, moving from "technological breakthroughs" to "clinical popularization" [1][4]. Group 1: Surgical Procedure and Patient Background - The patient, a 61-year-old woman, had a 10-year history of osteoarthritis in both knees, with worsening pain and limited mobility in the right knee over the past two years, necessitating surgical intervention [3]. - Previous treatments, including sodium hyaluronate injections, failed to alleviate her symptoms, leading to the decision to use the HX robotic arm for the surgery due to the high precision and functional recovery requirements [3]. Group 2: Technology and Innovation - The HX robotic arm, developed by Yuanhua Intelligent Technology's subsidiary, is the only domestic company that has achieved full-chain independent research and development of core components for orthopedic surgical robots [4]. - The system utilizes preoperative CT data for 3D reconstruction, quantifying lower limb alignment and osteotomy range to create a personalized surgical plan [6]. - During the surgery, the optical tracking system provided real-time navigation with sub-millimeter accuracy, ensuring that the osteotomy thickness, prosthetic angle, and limb alignment met physiological requirements [6]. Group 3: Clinical Outcomes and Implications - The HX robotic arm maintained prosthetic position accuracy within sub-millimeter levels, significantly reducing postoperative pain, prosthetic loosening, and revision risks, while enabling smaller incisions and less trauma for faster patient recovery [6]. - Since its establishment in 2018, Yuanhua Intelligent has adhered to an independent technology route, breaking the international monopoly on high-end surgical robot core components and addressing the industry's long-standing reliance on imports [6]. - The successful implementation of the HX robotic arm at a top-tier hospital not only validates its safety and effectiveness in complex clinical scenarios but also demonstrates the adaptability and clinical value of domestic high-end medical equipment [6].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 156.55, representing a potential upside of 17% from the current price of RMB 132.90 [1][9]. Core Insights - The company achieved a revenue of RMB 10.30 billion in 2024, a decrease of 9.73% year-on-year, and a net profit attributable to shareholders of RMB 1.26 billion, down 36.08% [9][10]. - In Q1 2025, the company reported a revenue of RMB 2.48 billion, an increase of 5.42%, and a net profit of RMB 370 million, up 1.87% [9][10]. - The company is expected to have EPS of RMB 2.20 in 2025 and RMB 2.65 in 2026, with a new forecast for 2027 at RMB 3.18 [9][10]. Financial Summary - Revenue and Profit Forecasts: - 2023A: Revenue of RMB 11.41 billion, Net Profit of RMB 1.97 billion - 2024A: Revenue of RMB 10.30 billion, Net Profit of RMB 1.26 billion - 2025E: Revenue of RMB 12.44 billion, Net Profit of RMB 1.81 billion - 2026E: Revenue of RMB 14.97 billion, Net Profit of RMB 2.18 billion - 2027E: Revenue of RMB 17.99 billion, Net Profit of RMB 2.62 billion [2][5]. - Key Financial Ratios: - Net Asset Return Rate (ROE) is projected to be 6.3% in 2024 and 10.2% in 2027 [2][5]. - The Price-to-Earnings (P/E) ratio is expected to be 86.80 in 2024 and decrease to 41.84 by 2027 [2][5]. Market Position and Strategy - The company continues to increase its domestic market share, with a structural growth of over 3 percentage points year-on-year, particularly in high-end products [10][11]. - In 2024, the company achieved overseas revenue of RMB 2.27 billion, a growth of 35.07%, accounting for 22% of total revenue [11][12]. - The service revenue reached RMB 1.36 billion in 2024, representing a 26.80% increase and accounting for 13.16% of total revenue [12]. Conclusion - The report highlights the company's strong position in the medical imaging equipment sector, supported by ongoing domestic policy and international market expansion, justifying the "Outperform" rating and the target price increase [9][10][11].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 156.55, representing a potential upside of 17% from the current price of RMB 132.90 [1][10]. Core Insights - The company achieved a revenue of RMB 10.30 billion in 2024, a decrease of 9.73% year-on-year, with a net profit attributable to shareholders of RMB 1.26 billion, down 36.08% [5][10]. - In Q1 2025, the company reported a revenue of RMB 2.48 billion, an increase of 5.42%, and a net profit of RMB 370 million, up 1.87% [5][10]. - The company is expected to have EPS of RMB 2.20 in 2025 and RMB 2.65 in 2026, with a new forecast for 2027 at RMB 3.18 [5][10]. Domestic Market Performance - The company continues to increase its domestic market share, with a revenue of RMB 7.66 billion in 2024, reflecting a decline of 19.43% [11]. - The company achieved structural breakthroughs with a differentiated strategy, increasing overall business share by over 3 percentage points year-on-year, with high-end products contributing nearly 5 percentage points [11]. International Market Expansion - The company reported overseas revenue of RMB 2.27 billion in 2024, an increase of 35.07%, accounting for 22% of total revenue [12]. - The company has established a marketing team of over 700 and more than 1,000 service engineers, covering over 200 cities in more than 85 countries [12]. Service Revenue Growth - In 2024, service revenue reached RMB 1.36 billion, up 26.80%, accounting for 13.16% of total revenue [13]. - The after-sales service gross profit margin increased by 1.71 percentage points to 63.43%, supporting overall profitability [13].